Teladoc Health Inc vs Thomson Reuters Corp — how do they compare? Teladoc Health Inc trades at $6.1 (market cap $1.14B), while Thomson Reuters Corp trades at $97 (market cap $42.75B). The key difference: Thomson Reuters Corp is far larger — about 37.5× Teladoc Health Inc's market cap, and Thomson Reuters Corp pays a 2.65% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| TDOC | TRI | |
|---|---|---|
Market Cap | $1.14B | $42.75B |
Sector | Health | Industrials |
52-Week High | $9.72 | $173.48 |
52-Week Low | $4.47 | $76.55 |
Enterprise Value | $1.40B | $45.37B |
Dividend Yield | — | 2.65% |
Signals from Pluang's Aura AI — not financial advice
TDOC trades at $6.26, down 0.32% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $200.32 million in 2025, though revenue remains stable at $2.53 billion. Recent news includes the appointment of a new CFO and ongoing legal investigations, while analyst consensus is a $8.88 price target with a hold-heavy rating.
The outlook is mixed: valuation metrics like P/S of 0.45 and EV/EBITDA of 6.5 suggest potential undervaluation, but persistent losses and negative cash flow in 2025 pose risks. Upside hinges on profitability improvements from its integrated care segment, while competitive pressures and weak BetterHelp performance are headwinds.
Thomson Reuters (TRI) trades at $98.81, down 6.5% in 24 hours, with a bearish technical signal and support near $97. The company reported Q2 2026 EPS of $0.99, beating estimates, and raised full-year revenue guidance. Revenue grew 9% organically, with strong performance in Legal, Corporates, and Tax segments. Net income margin is 21.22%, and the P/E ratio is 26.03. Recent news highlights AI expansion with the launch of the proprietary Thomson-1 LLM and a cybersecurity incident affecting its case management system.
Outlook is mixed: robust recurring revenue and AI adoption support growth, but the stock faces near-term pressure from the price drop and cybersecurity risks. Analysts maintain a buy consensus with a $113 price target, implying 14% upside. Key risks include execution on AI initiatives, competitive pressures, and potential fallout from the security breach.
Trailing returns across standard periods
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →